LabConnect Announces Global Sample Processing Network
Seattle, January 22, 2019 (Business Wire) – LabConnect, a leading global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organizations, is pleased to announce a new service: LabConnect’s global sample processing network (GSPN). This GSPN will offer a comprehensive global solution for sample preparation and processing requirements.
Given the rapid growth in immuno-oncology and cell gene therapies, high-quality and expeditious sample processing is required within today’s trials. Balancing turnaround time requirements with the desire for processing consistency across global sites is an industry-wide challenge.
With more worldwide locations than any other central laboratory services provider, LabConnect addresses this challenge by significantly minimizing shipping time from site to processing lab, optimizing viability for time-sensitive samples. Proprietary packaging, standardized analyst certification and centralized performance monitoring combine to ensure global consistency. Additionally, LabConnect’s web portal allows easy access to study-wide sample processing quality metrics. LabConnect’s GSPN supports global research protocols by offering reliable worldwide sample processing.
Jeff Mayhew, chief development officer at LabConnect says, “LabConnect has recognized the growing need for high quality sample processing in the industry’s increasingly complex studies. GSPN is our innovative approach to addressing these evolving demands. GSPN combines our extensive global footprint with our global expertise in sample processing, offering the unique ability to meet the most challenging of study requirements.”
About LabConnect
Founded in 2002, LabConnect comprises a network of global central laboratories with services including routine and esoteric laboratory testing, clinical kit building, sample management, biorepository, and scientific operations support services for biopharmaceutical, medical device, and contract research organizations around the world. Learn more at labconnectllc.com or connect with LabConnect on LinkedIn.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
